Expression of p16, p53, and Ki-67 in colorectal adenocarcinoma: A study of 356 surgically resected cases

Hepato-Gastroenterology

Volumn 57, Issue 101, 2010, Pages 734-740

  Huh, Jung Wook ^a   Lee, Jae Hyuk ^a   Kim, Hyeong Rok ^a  

^a Chonnam National University   (South Korea)

Author keywords

Colorectal adenocarcinoma; Ki 67; p16; p53

Indexed keywords

KI 67 ANTIGEN; PROTEIN P16; PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURGERY; COLORECTAL ADENOCARCINOMA; COLORECTAL CARCINOMA; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCINOUS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; RECTAL NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78149239622     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Alvarado MD, Jensen EH, Yeatman TJ: The potential role of gene expression in the management of primary and metastatic colorectal cancer. Cancer Control 2006; 13:27-31.
3. Nigro JM, Baker SJ, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342:705-708.
4. Bosari S, Viale G: The clinical significance of p53 aberrations in human tumours. Virchows Arch 1995; 427:229-241.
5. Gerdes J, Lemke H, Baisch H, et al: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133:1710-1715.
6. Kim WY, Sharpless NE: The regulation of INK4/ARF in cancer and aging. Cell 2006; 127:265-275.
7. Lam AK, Ong K, Giv MJ, Ho YH: p16 expression in colorectal adenocarcinoma: marker of aggressiveness and morphological types. Pathology 2008; 40:580-585.
8. Cui X, Shirai Y, Wakai T, et al: Aberrant expression of pRb and p16(INK4), alone or in combination, indicates poor outcome after resection in patients with colorectal carcinoma. Hum Pathol 2004; 35:1189-1195.
9. Tada T, Watanabe T, Kazama S, et al: Reduced p16 expression correlates with lymphatic invasion in colorectal cancers. Hepatogastroenterology 2003; 50:1756-1760. (Pubitemid 37467927)
10. Huh JW, Kim HR, Cho SH, Kim YJ: Clinical significance of p53 and Ki-67 expression in colorectal cancer. J Korean Soc Coloproctol 2009; 25:91-96.
11. Reed JA, Manahan LJ, Park CS, Brigati DJ: Complete one-hour immunocytochemistry based on capillary action. Biotechniques 1992; 13:434-443.
12. Huh JW, Kim HR, Kim YJ, et al: Expression of standard CD44 in human colorectal carcinoma: association with prognosis. Pathol Int 2009; 59:241-246.
13. Mueller JD, Haegle N, Keller G, et al: Loss of heterozygosity and microsatellite instability in de novo versus ex-adenoma carcinomas of the colorectum. Am J Pathol 1998; 153:1977-1984.
14. Lu DW, El-Mofty SK, Wang HL: Expression of p16, Rb, and p53 proteins in squamous cell carcinomas of the anorectal region harboring human papillomavirus DNA. Mod Pathol 2003; 16:692-699.
15. Weidner N, Moore DH, Vartanian R: Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody. Hum Pathol 1994; 25:337-342.
16. Bouzourene H, Gervaz P, Cerottini JP, et al: p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer 2000; 36:1008-1015.
17. Lanza G, Jr., Maestri I, Dubini A, et al: p53 expression in colorectal cancer: relation to tumor type, DNA ploidy pattern and short-term survival. Am J Clin Pathol 1996; 105:604-612.
18. Zeng ZS, Sarkis AS, Zhang ZF, et al: p53 nuclear overexpression: an independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 1994; 12:2043-2050.
19. Yamaguchi A, Nakagawara G, Kurosaka Y, et al: p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer 1993; 68:399-402.
20. Watanabe T, Wu TT, Catalano PJ, et al: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344:1196-1206.
21. Ahnen DJ, Feigl P, Quan G, et al: Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 1998; 58:1149-1158.
22. Soong R, Grieu F, Robbins P, et al: p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 1997; 3:1405-1411.
23. Amundson SA, Myers TG, Fornace AJJr: Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 1998; 17:3287-3299.
24. Kirsch DG, Kastan MB: Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol 1998;1 6:3158-3168.
25. Baretton GB, Diebold J, Christoforis G, et al: Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer 1996; 77:255-264.
26. Leahy DT, Salman R, Mulcahy H, et al: Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis. J Pathol 1996; 180:364-370. (Pubitemid 27014072)
27. Watson AJ, Merritt AJ, Jones LS, et al: Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Br J Cancer 1996; 73:889-895.
28. Russo A, Bazan V, Iacopetta B, et al: The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005; 23:7518-7528.
29. Iacopetta B: Are there two sides to colorectal cancer? Int J Cancer 2002; 101:403-408.
30. Kapiteijn E, Liefers GJ, Los LC, et al: Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol 2001; 195:171-178.
31. Birkenkamp-Demtroder K, Olesen SH, Sorensen FB, et al: Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut 2005; 54:374-384.
32. Giaginis C, Georgiadou M, Dimakopoulou K, et al: Clinical significance of MCM-2 and MCM-5 expression in colon cancer: association with clinicopathological parameters and tumor proliferative capacity. Dig Dis Sci 2009; 54:282-291.
33. Sun XF, Carstensen JM, Zhang H, et al: Prognostic significance of p53 nuclear and cytoplasmic overexpression in right and left colorectal adenocarcinomas. Eur J Cancer 1996; 32:1963-1967.
34. Bosari S, Viale G, Bossi P, et al: Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 1994; 86:681-687.
35. Hilska M, Collan YU, VJ OL, et al: The significance of tumor markers for proliferation and apoptosis in predicting survival in colorectal cancer. Dis Colon Rectum 2005; 48:2197-2208.
36. Allegra CJ, Paik S, Colangelo LH, et al: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003; 21:241-250.
37. Liu XP, Tsushimi K, Tsushimi M, et al: Expression of p21(WAF1/CIP1) and p53 proteins in gastric carcinoma: its relationships with cell proliferation activity and prognosis. Cancer Lett 2001; 170:183-189.
38. Kanai T, Konno H, Maruyama K, et al: p53 overexpression and proliferative activity do not correlate with lymph node metastasis in early gastric cancer. Eur Surg Res 1997; 29:35-41.
39. Chan AO, Luk JM, Hui WM, Lam SK: Molecular biology of gastric carcinoma: from laboratory to bedside. J Gastroenterol Hepatol 1999; 14:1150-1160.
40. Prives C, Hall PA: The p53 pathway. J Pathol 1999; 187:112-126.
41. Chen G, Burger MM: p150 overexpression in gastric carcinoma: the association with p53, apoptosis and cell proliferation. Int J Cancer 2004; 112:393-398.
42. Ishii HH, Gobe GC, Pan W, et al: Apoptosis and cell proliferation in the development of gastric carcinomas: associations with c-myc and p53 protein expression. J Gastroenterol Hepatol 2002; 17:966-972.